关注
Steven I. Blum
Steven I. Blum
Health Economics & Outcomes Research, Forest Research Institute
在 frx.com 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non–small-cell lung cancer in CheckMate 227
JR Brahmer, JS Lee, TE Ciuleanu, R Bernabe Caro, M Nishio, L Urban, ...
Journal of Clinical Oncology 41 (6), 1200-1212, 2023
1782023
Assessment of patient-reported outcome instruments to assess chronic low back pain
A Ramasamy, ML Martin, SI Blum, H Liedgens, C Argoff, R Freynhagen, ...
Pain Medicine 18 (6), 1098-1110, 2017
712017
Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD
PY Andrew, A Guérin, DP de Leon, K Ramakrishnan, EQ Wu, M Mocarski, ...
Respiratory medicine 105 (12), 1861-1871, 2011
712011
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label …
D Cella, RJ Motzer, C Suarez, SI Blum, F Ejzykowicz, M Hamilton, ...
The Lancet Oncology 23 (2), 292-303, 2022
702022
Burden of illness of diabetic peripheral neuropathic pain: a qualitative study
M Brod, B Pohlman, SI Blum, A Ramasamy, R Carson
The patient-patient-centered outcomes research 8, 339-348, 2015
622015
Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis
AP Yu, H Yang, EQ Wu, J Setyawan, M Mocarski, S Blum
Journal of Medical Economics 14 (3), 315-323, 2011
502011
First-line nivolumab plus ipilimumab versus chemotherapy in advanced NSCLC with 1% or greater tumor PD-L1 expression: patient-reported outcomes from CheckMate 227 Part 1
M Reck, TE Ciuleanu, JS Lee, M Schenker, C Audigier-Valette, ...
Journal of Thoracic Oncology 16 (4), 665-676, 2021
352021
Symptoms and impacts in anemia of chronic kidney disease
SD Mathias, SI Blum, V Sikirica, KL Johansen, HH Colwell, T Okoro
Journal of Patient-Reported Outcomes 4, 1-10, 2020
262020
Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis
JE Signorovitch, TM Samuelson, K Ramakrishnan, M Marynchenko, ...
Current medical research and opinion 28 (4), 591-599, 2012
252012
Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients …
EQ Wu, AP Yu, V Lauzon, K Ramakrishnan, M Marynchenko, ...
Annals of Pharmacotherapy 45 (4), 441-451, 2011
252011
Perioperative nivolumab in resectable lung cancer
T Cascone, MM Awad, JD Spicer, J He, S Lu, B Sepesi, F Tanaka, ...
New England Journal of Medicine 390 (19), 1756-1769, 2024
242024
Mixed-methods development of a new patient-reported outcome instrument for chronic low back pain: Part 1—the Patient Assessment for Low Back Pain-Symptoms (PAL-S)
ML Martin, SI Blum, H Liedgens, DM Bushnell, KP McCarrier, NV Hatley, ...
Pain 159 (6), 1045-1055, 2018
242018
Development and validation of the Diabetic Peripheral Neuropathic Pain Impact (DPNPI) measure, a patient-reported outcome measure
M Brod, SI Blum, DM Bushnell, A Ramasamy
Quality of Life Research 24, 3001-3014, 2015
202015
CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in …
J Edeline, T Yau, JW Park, M Kudo, KH Han, P Mathurin, P Merle, RS Finn, ...
Journal of Clinical Oncology 38 (4_suppl), 483-483, 2020
192020
Patient-reported outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line nivolumab plus cabozantinib versus sunitinib: the CheckMate 9ER trial.
D Cella, TK Choueiri, SI Blum, F Ejzykowicz, M Hamilton, J Zhang, ...
Journal of Clinical Oncology 39 (6_suppl), 285-285, 2021
182021
Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder
SI Blum, S Tourkodimitris, A Ruth
Journal of affective disorders 170, 230-236, 2015
142015
Development and adaptation of patient-reported outcome measures for patients who experience itch associated with primary biliary cholangitis
ML Martin, L Stassek, SI Blum, AV Joshi, D Jones
Journal of Patient-Reported Outcomes 3, 1-11, 2019
132019
Scale development with small samples: A new application of longitudinal item response theory
CR Houts, R Morlock, SI Blum, MC Edwards, RJ Wirth
Quality of Life Research 27, 1721-1734, 2018
132018
Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced …
J Chang, YL Wu, S Lu, J Wang, T Mok, L Zhang, J Feng, L Wu, HY Tu, ...
Lung cancer 165, 71-81, 2022
122022
Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer …
JR Brahmer, JS Lee, TE Ciuleanu, R Bernabe Caro, M Nishio, L Urban, ...
Journal of Clinical Oncology 40 (17_suppl), LBA9025-LBA9025, 2022
102022
系统目前无法执行此操作,请稍后再试。
文章 1–20